Repetitive transcranial magnetic stimulation (rTMS) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression since 2008.
Repetitive transcranial magnetic stimulation (rTMS) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression since 2008.
Repetitive transcranial magnetic stimulation (rTMS) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression since 2008.
Repetitive transcranial magnetic stimulation (rTMS) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression since 2008.
Repetitive transcranial magnetic stimulation (rTMS) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression since 2008.
Expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD).
Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulatory technique used to modulate orbital frontal corticostriatal (OFC) activity and clinical symptomatology for psychiatric disorders involving OFC dysfunction.
It is also suggested that while transcranial magnetic stimulation is a growing area of research as a novel depression treatment, targeting the lateral orbitofrontal cortex with this technique could be a beneficial future treatment.
To present a case series of the use of adjunctive continuous theta burst (cTBS) to the right dorsolateral prefrontal cortex (DLPFC) to treat anxiety symptoms.